Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Preaching to the converted

Debt and biotech have always had an oil and water feel, given that most companies don't have the cash flow to meet the interest payments. But that hasn't kept investors from throwing money at companies in exchange for IOUs over the years. Now the convert market has hotted up again, with $1.2 billion of debt pricing last week, bringing to $1.7 billion

Read the full 628 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers